Leaders in Pharmaceutical Business Intelligence (LPBI) Group

generation

by pene-

tration of

multiple

markets

simulta-

neously,

exploit economic benefits from

internal

vertical

integration,

product

differentiation

and

diversification

across product

lines and

markets

Application development

(b) product repurposing

(c) Beta Testing

or Clinical Trials

Change in Organizational

Structure by

acquiring

economies of

scale and

increasing

capacities for

doing same

functions in

bigger scale

Change in

Organization

Structure by

integration of

additional

functionality

to existing

workflows &

production

processes,

capability

augmentation

by new

expertise (R&D, Production,

Marketing) via acquisitions

Application of proprietary Intellectual Property & Knowledge dissemination to Members or event Attendees

scientific

CONTENT

creation

Analytics & Discovery: Text Mining Corpus of Article, Books, e-Proceeding

containment

by new

efficiencies

Kaiser

Perma-nente & BlueCross/

BlueShield

(b) product repurposing

(c) Beta Testing or Clinical Trials

Analytics & Discovery: Text Mining Corpus of Article, Books, e-Proceeding

Private & Public Institutions

Care Services (Contract-based Out-sourcing)

-driven

by penetration of multiple markets simulta-neously, exploit economic benefits

from internal vertical integration, product differentiation and diversifi-cation across product lines and   markets

Application development

(b) product repurposing

(c) Beta

Testing or Clinical Trials

mation Syndica

tors

(Reuters Clarivate

&

Springer)

Change in Organizational Structure by acquiring economies of scale and increasing capacities for doing same functions in bigger scale

Change in

Organization

Structure by

integration of

additional

functionality

to existing

workflows &

production

processes,

capability

augmentation

by new

expertise (R&D, Production,

Marketing) via acquisitions

Application

of

proprietary Intellectual Property

&

Knowledge dissemi-nation to Members or event Attendees

scientific

CONTENT

creation

& MOOC

Analytics & Discovery: Text Mining Corpus of Article, Books, e-Proceeding

containment

by new

efficiencies

Holding Company and Investment Banker

Potential Use by Acquirer:

Invest in product marketing of three Lines of Business

Class I,II,III

• Internet Brands of KKR

http://www.kkr.com/

• Temasek

https://www.temasek.com.sg/en/index.html

• NMC

http://www.newmountaincapital.com/

• Generex

http://www.generex.com/

Information Technology Companies – Health Care

Potential Use by Acquirer:

Use contents in application development

Class I,II,III 

• Amazon Web Services (AWS)
• Google- Verily
• Apple Health
• Microsoft
• IBM-Watson
• Oracle Healthcare

Scientific Publishers

Potential Use by Acquirer:

Horizontal merger

Class I,II,III 

• Wolters Kluwer
• Elsevier
• John Wiley
• CHI

Big Pharma

Potential Use by Acquirer:

Vertical Integration with a production factor

Class I,II,III

1. Drug Discovery Process

2. Clinical Trial

3. Drug Repurposing

https://pharmaceuticalintelligence.com/2019/02/14/drug-repurposing-hub-library-broadinstitute-mit-harvard/

• J&J
• Roche
• Novartis
• Pfizer
• Bayer
• Merck
• GSK
• Sanofi
• Abbvie
• Abbott
• Eli Lilly
• Amgen
• BMS
• Gilead
• AstraZeneca
• TEVA
• BI
• NovoNordisk
• Allergen
• Takeda
• Shire
• Celgene
• Biogen

Internet Health Care Media

 Potential Use by Acquirer:

Horizontal merger

Class I,II,III

• MedScape

–        676,000 active US Physicians

–        2,000,000 active US HCP’s (non-Physicians)

• UptoDate

Education

Potential Use by Acquirer:

Content is King

Class I,II

• MOOC
• Coursera

Health Insurance Companies & HMOs

Potential Use by Acquirer:

Optimization of Treatment: Efficacy vs cost of treatment

Class I,II,III

• United Health
• Kaiser Permanente
• BC/BS

Medical and Pharma Associations

Potential Use by Acquirer:

Information for Members

Class I,II,III 

• Chinese College of Cardiology – 350,000 MDs
• Chinese College of Oncology
• Germany
• Japan
• India
• Canada

  Medical Education

Potential Use by Acquirer:

Content is King

Class I,II,III

• 250 Medical Schools in the US
• Europe

In 2019, Class II, e-Books are in Use in Medical Schools in the State of Pennsylvania for curriculum development:

Series A: Volume 3 – Epigenetics, Genetics and Genomics [Jefferson Medical School, Philadelphia]

Series B: Volume 1 –  Genomics & Personalized Medicine [Temple University, Philadelphia]

Series C: Volume 1,2 – Cancer [Temple University, Philadelphia]

Series E: Volume 1 – Voices of Patients  [Jefferson Medical School, Philadelphia]

Information Syndicators

Potential Use by Acquirer:

Text Mining

Class I,II,III

• US – Reuters’ Clarivate

They are operating in the same arena.

They can use our system to other domains.

They can develop it as part of their comprehensive offer.

New connections and ideas they will bring on board.

• Europe – Springer

Global Biotech & Pharmaceutical Conference Organizers

Potential Use by Acquirer:

Information for Attendees

Class I,II,III

• US – Cambridge Healthtech Institute – Class I,II,III
• BIO Asia International Conference – BIO
• CPhI North America 2019 | No.1 Biotech Conference‎
• 25th Asia Pacific Biotechnology Congress
• BIO-Europe Spring® | Vienna, Austria. Mar 25-27‎
• BioTech Conference 2019 London | UK. May 7-8. 

CRO & CRA

Potential Use by Acquirer:

Text Mining for Indication and off label in Clinical Trial Design and After Market Efficacy Monitoring

Class I,II,III 

• Top 10 on List of CRO in the US
• Top 10 on List of Global CRO